Sign In
Buy G
Genpact Earnings Calls
| Release date | Nov 06, 2025 |
| EPS estimate | $0.90 |
| EPS actual | $0.97 |
| EPS Surprise | 7.78% |
| Revenue estimate | 1.288B |
| Revenue actual | 1.291B |
| Revenue Surprise | 0.268% |
| Release date | Aug 07, 2025 |
| EPS estimate | $0.85 |
| EPS actual | $0.88 |
| EPS Surprise | 3.53% |
| Revenue estimate | 1.255B |
| Revenue actual | 1.254B |
| Revenue Surprise | -0.0625% |
| Release date | May 07, 2025 |
| EPS estimate | $0.80 |
| EPS actual | $0.84 |
| EPS Surprise | 5.00% |
| Revenue estimate | 1.208B |
| Revenue actual | 1.215B |
| Revenue Surprise | 0.538% |
| Release date | Feb 06, 2025 |
| EPS estimate | $0.86 |
| EPS actual | $0.91 |
| EPS Surprise | 5.81% |
| Revenue estimate | 1.228B |
| Revenue actual | 1.249B |
| Revenue Surprise | 1.65% |
Last 4 Quarters for Genpact
Below you can see how G performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 06, 2025 |
| Price on release | $49.40 |
| EPS estimate | $0.86 |
| EPS actual | $0.91 |
| EPS surprise | 5.81% |
| Date | Price |
|---|---|
| Jan 31, 2025 | $48.69 |
| Feb 03, 2025 | $48.93 |
| Feb 04, 2025 | $49.36 |
| Feb 05, 2025 | $49.41 |
| Feb 06, 2025 | $49.40 |
| Feb 07, 2025 | $54.95 |
| Feb 10, 2025 | $54.44 |
| Feb 11, 2025 | $54.77 |
| Feb 12, 2025 | $54.90 |
| 4 days before | 1.46% |
| 4 days after | 11.13% |
| On release day | 11.23% |
| Change in period | 12.75% |
| Release date | May 07, 2025 |
| Price on release | $49.55 |
| EPS estimate | $0.80 |
| EPS actual | $0.84 |
| EPS surprise | 5.00% |
| Date | Price |
|---|---|
| May 01, 2025 | $49.24 |
| May 02, 2025 | $49.71 |
| May 05, 2025 | $49.57 |
| May 06, 2025 | $49.68 |
| May 07, 2025 | $49.55 |
| May 08, 2025 | $42.04 |
| May 09, 2025 | $42.46 |
| May 12, 2025 | $43.54 |
| May 13, 2025 | $43.72 |
| 4 days before | 0.630% |
| 4 days after | -11.77% |
| On release day | -15.16% |
| Change in period | -11.21% |
| Release date | Aug 07, 2025 |
| Price on release | $41.72 |
| EPS estimate | $0.85 |
| EPS actual | $0.88 |
| EPS surprise | 3.53% |
| Date | Price |
|---|---|
| Aug 01, 2025 | $42.49 |
| Aug 04, 2025 | $42.55 |
| Aug 05, 2025 | $42.37 |
| Aug 06, 2025 | $42.20 |
| Aug 07, 2025 | $41.72 |
| Aug 08, 2025 | $43.54 |
| Aug 11, 2025 | $43.25 |
| Aug 12, 2025 | $43.31 |
| Aug 13, 2025 | $44.22 |
| 4 days before | -1.81% |
| 4 days after | 5.99% |
| On release day | 4.36% |
| Change in period | 4.07% |
| Release date | Nov 06, 2025 |
| Price on release | $38.39 |
| EPS estimate | $0.90 |
| EPS actual | $0.97 |
| EPS surprise | 7.78% |
| Date | Price |
|---|---|
| Oct 31, 2025 | $38.15 |
| Nov 03, 2025 | $38.12 |
| Nov 04, 2025 | $38.43 |
| Nov 05, 2025 | $38.82 |
| Nov 06, 2025 | $38.39 |
| Nov 07, 2025 | $44.49 |
| Nov 10, 2025 | $44.28 |
| Nov 11, 2025 | $44.89 |
| Nov 12, 2025 | $45.54 |
| 4 days before | 0.629% |
| 4 days after | 18.62% |
| On release day | 15.89% |
| Change in period | 19.37% |
Genpact Earnings Call Transcript Summary of Q3 2025
Genpact reported a strong Q3 2025: revenue of $1.291B (+6.6% y/y) beat the high end of guidance by $21M. Advanced Technology Solutions (ATS) accelerated to +20% y/y and now drives a large portion of growth; ATS represented 24% of Q3 revenue and has driven more than half of year-to-date growth. Gross margin expanded to 36.4% and adjusted operating income margin was 17.7%; adjusted diluted EPS was $0.97 (+14% y/y), growing faster than revenue. Management highlighted product and go-to-market momentum: three new AI/agentic product suites (AI Maestro, Genpact Insurance Policy Suite, Record-to-Report Suite), ~100 clients in the AI Gigafactory, and 330+ GenAI solutions in-market. Agentic contract value is rising rapidly, with ~30% of awarded agentic contract value year-to-date from new clients. Partnerships grew strongly (+56% partner-related revenue y/y) and hiring in AI/data talent is accelerating. Bookings/pipeline remain healthy (five large deals closed in Q3), though large transformational deals can have longer sales cycles. Cash/operating cash flow remain healthy (operating cash flow of $308M including a $45M advanced client payment; ex-payment $228M), and capital return continued ($119M this quarter; YTD $272M). Management raised full-year revenue guidance to +6.1%–6.4% and adjusted diluted EPS to $3.60–$3.61; Q4 revenue guidance ~ $1.298B–$1.311B. Key investor takeaways: durable margin expansion, accelerating high-margin ATS growth and product momentum in agentic/GenAI, healthy pipeline and bookings, continued capital returns while investing in AI talent and productization.
